Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.57 USD
+0.03 (1.77%)
Updated Aug 30, 2024 03:59 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 1 - 20 ( 138 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
2Q24 Margin Improvement Ahead of Growth, Upgrade to Buy, PT to $2.50
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Steady in Core Markets, But Gearing Up for a Catalyst-Rich H2/24
Provider: Ventum Capital Markets
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Debt Markets Sizzling, Verano/Cannabist Cook Up an Asset Acquisition
Provider: Ventum Capital Markets
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
2Q24 Preview, Cost Controls in Place for FL, OH, NY Sales Ramp in ''25
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
U.S. Cannabis Industry: 2Q24 Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Another Strong Quarter as Costs Drain from the Business
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
1Q24 In-Line, Operational Improvements Continue Ahead of OH
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis ReHash: DEA Intends to Move to Schedule 3, Investors Not Pricing It In
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Good End to the Year of The Core; Improvements Ahead in ''24
Provider: Wedbush Securities Inc.
Analyst: PASCARELLI G